Browsing Tag
ESMO
4 posts
Immutep (ASX: IMM) surges 48% on FDA orphan drug designation: Is the STS pivot the new thesis?
Immutep (ASX: IMM) jumped 48% after the FDA granted orphan drug status for eftilagimod alfa in soft tissue sarcoma. Here is what the EFTISARC-NEO data means for the investment case.
Avacta (AVCT) at AACR 2026: What the San Diego data presentations actually mean if you’re holding shares through the trial
Avacta Therapeutics (AIM: AVCT) is presenting two posters at AACR 2026 in San Diego. Here is what investors need to understand about conference data versus clinical trial readouts and which milestones actually move the stock.
How Celcuity Inc.’s gedatolisib trial results sent its stock soaring 46% in a single morning
Celcuity stock surged 46% after Phase 3 trial data showed strong efficacy for gedatolisib in HR+/HER2- breast cancer. Find out what this means for investors.
Akeso Biopharma raises $250m to accelerate international clinical trials
Akeso Biopharma has successfully raised approximately $250 million through a share placement, drawing significant recognition from international investment…